An Open-Label, Phase II Study of the Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (PIPF-002)

An Open-Label, Phase II Study of the Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (PIPF-002)

Abstract Introduction PIPF-002 was a phase 2, multicenter, open-label study of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF) or other types of pulmonary fibrosis (PF). PIPF-002 terminated after pirfenidone became commercially available in the United States. The goal of PIPF-002 wa...

Full description

Bibliographic Details
Main Authors: Mark H. Gotfried, Carlos E. Girod, Danielle Antin-Ozerkis, Tracy Burgess, Indiana Strombom, John L. Stauffer, Klaus-Uwe Kirchgaessler, Maria L. Padilla
Format: Article
Language:English
Published: Adis, Springer Healthcare 2018-06-01
Series:Pulmonary Therapy
Subjects:
IPF
Pirfenidone
Safety
Online Access:https://doi.org/10.1007/s41030-018-0053-y

Internet

https://doi.org/10.1007/s41030-018-0053-y

Similar Items